Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. BRTX
BRTX logo

BRTX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy BioRestorative Therapies Inc (BRTX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
0.370
1 Day change
-6.06%
52 Week Range
1.890
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

BRTX is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is trading near $0.40 with only a minor daily move, but the broader setup is weak: bearish moving averages, a negative MACD histogram, no strong proprietary buy signals, no recent news catalyst, neutral insider/hedge fund activity, and no financial quarter data to support a long-term bullish thesis. For an impatient investor who does not want to wait for a better entry, this is not an attractive purchase.

Technical Analysis

Current technicals are mixed to bearish. MACD histogram is -0.00507 and below zero, indicating weak momentum, though it is slightly contracting. RSI_6 at 60.526 is neutral to mildly constructive, but it does not confirm a strong breakout. The moving average structure is bearish with SMA_200 > SMA_20 > SMA_5, which suggests the longer-term trend remains weak. Price at 0.4039 is just above pivot 0.39 and below resistance 0.419, so upside is limited unless it can reclaim resistance decisively. Support sits at 0.36 and 0.342. The stock trend model also points lower over the next week and month.

Positive Catalysts

  • No news in the recent week. The only mild positive is that the stock finished slightly above the prior close, and the price is trading near the pivot level, which could allow a short-term bounce if momentum improves. However, there are no strong event-driven catalysts, no bullish proprietary signals, and no meaningful insider or institutional accumulation trend.

Neutral/Negative Catalysts

  • No recent news, no recent congress trading data, and no financial snapshot available. Hedge funds are neutral and insiders are neutral, so there is no visible informed buying support. The technical trend is bearish, MACD is negative, and similar candlestick pattern analysis suggests negative forward returns over the next day, week, and month. SwingMax and AI Stock Picker both show no signal, which removes the strongest short-term bullish triggers.

Financial Performance

Latest quarter financials were not provided due to a data error, so there is no reliable quarterly revenue, earnings, or growth trend to support a long-term buy case. Without visible latest-quarter season results, the fundamental picture cannot justify aggressive buying for a beginner investor.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no evidence of a recent Wall Street upgrade or target increase. Based on the available information, Wall Street sentiment appears neutral to cautious rather than bullish.

Wall Street analysts forecast BRTX stock price to rise
1 Analyst Rating
Wall Street analysts forecast BRTX stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.396
sliders
Low
8
Averages
8
High
8
Current: 0.396
sliders
Low
8
Averages
8
High
8
Roth Capital
Jonathan Aschoff
Buy
downgrade
$18 -> $15
AI Analysis
2026-04-02
Reason
Roth Capital
Jonathan Aschoff
Price Target
$18 -> $15
AI Analysis
2026-04-02
downgrade
Buy
Reason
Roth Capital analyst Jonathan Aschoff lowered the firm's price target on BioRestorative Therapies to $15 from $18 and keeps a Buy rating on the shares. In the company's updated interim blinded results from its Phase 2 trial evaluating BRTX-100 in cLDD patients, the press release contained the "wrong" patient numbers for over-50% improvement, though the percent of patients that achieved the thresholds at the timepoints was still accurate, the analyst tells investors in a research note. Despite the large caveat that comes with drawing conclusions from blinded data, the most recent data continue the encouraging trend, and as long as the data trend continues, and response ends up falling along randomization lines as is currently assumed, it appears as if the trial will succeed, Roth added.

People Also Watch